Taiyen Biotech Co (TPE:1737) Total Current Liabilities: NT$960 Mil (As of Dec. 2025)


TPE:1737 Taiyen Biotech Co Ltd TPE:1737
83 GF Score
Price NT$31.90
GF Value NT$32.08
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Taiyen Biotech Co Total Current Liabilities?

Taiyen Biotech Co TPE:1737 83 Total Current Liabilities is NT$960 Mil as of Dec. 2025. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$32.08 (Fairly Valued). The stock has 1 warning sign investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Taiyen Biotech Co's total current liabilities for the quarter that ended in Dec. 2025 was NT$960

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Taiyen Biotech Co Total Current Liabilities Related Terms

Taiyen Biotech Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Taiyen Biotech Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiyen Biotech Co Total Current Liabilities Chart

Taiyen Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,305.38 926.05 1,101.03 1,165.15 959.89

Taiyen Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,165.15 1,025.73 1,264.62 1,034.63 959.89
TPE:1737
83GF Score
Taiyen Biotech Co Ltd TPE:1737
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiyen Biotech Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Taiyen Biotech Co's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=618.67+196.64
+Other Current Liabilities+Current Deferred Liabilities
=144.575+0
=960

Taiyen Biotech Co's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=618.67+196.64
+Other Current Liabilities+Current Deferred Liabilities
=144.575+0
=960

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of NT$960 Mil mean?
Taiyen Biotech Co (TPE:1737) has a Total Current Liabilities of NT$960 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Taiyen Biotech Co and its competitors.
Is Taiyen Biotech Co's Total Current Liabilities too high?
Taiyen Biotech Co's current Total Current Liabilities is NT$960 Mil. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Total Current Liabilities compare to PG and CL?
Taiyen Biotech Co's Total Current Liabilities of NT$960 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Consumer Packaged Goods company?
A good Total Current Liabilities depends on the Consumer Packaged Goods industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Taiyen Biotech Co and its competitors. Taiyen Biotech Co's current Total Current Liabilities is NT$960 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.08, compared to a current price of NT$31.90 — trading 0.6% below its estimated fair value. The current Total Current Liabilities is NT$960 Mil. Taiyen Biotech Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Total Current Liabilities is NT$960 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?

Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued. The current stock price of NT$31.90 is trading 0.6% below its estimated GF Value™ of NT$32.08. GuruFocus considers Taiyen Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1737:

  • Total Current Liabilities: NT$960 Mil
  • GF Value™: NT$32.08 vs. price of NT$31.90 (0.6% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiyen Biotech Co Business Description

Address No. 297, Section 1, Chien-Kang Road, South District, Tainan, TWN
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score

Get the complete analysis for TPE:1737

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.90
Price
NT$32.08
GF Value